



Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obixelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

June 2, 2026

- *The INDIGO study met its primary and all key secondary endpoints with statistically significant results -*
- *Obixelimab significantly lowered the total amount of glucocorticoid use and reduced glucocorticoid-related toxicities -*
- *A Biologics License Application (BLA) for obixelimab in IgG4-RD was submitted to the FDA in May -*

WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the presentation of additional positive data from the Phase 3 INDIGO trial evaluating obixelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at the [European Alliance of Associations for Rheumatology \(EULAR\) 2026 Congress](#), held from June 3-6, 2026, in London, England and published online by the [New England Journal of Medicine](#).

Collectively, the results consistently demonstrated reductions in disease activity including flare burden as well as glucocorticoid use and toxicity across multiple endpoints. The safety profile of obixelimab was comparable to placebo.

"The findings from the Phase 3 INDIGO trial for obixelimab in IgG4-RD mark a significant milestone for both the rheumatology community and patients living with this devastating disease," said Lonnie Moulder, Founder and Chief Executive Officer of Zenas. "These results further validate the significant clinical activity of obixelimab and its favorable safety and tolerability profile. Combined with its unique inhibitory mechanism of action, potential for steroid sparing and convenient at-home subcutaneous self-administration, we believe obixelimab has the opportunity to become an important first-line therapy for the long-term management of IgG4-RD. We are excited about the possibility of making this important therapy available to patients."

"Physicians currently have very few treatment options for patients living with this chronic, progressive and debilitating disease," said Emanuel Della Torre, M.D., Ph.D., Associate Professor of Medicine at Vita-Salute San Raffaele University in Milan, Italy. "The Phase 3 INDIGO data indicate obixelimab could offer a novel, highly active, self-administered therapy for people living with IgG4-RD, one that has the potential to avoid the safety concerns associated with chronic steroid use and long-term B cell depletion."

"INDIGO is the largest clinical trial ever conducted in IgG4-RD and represents the most extensive dataset to support the clinical activity of any advanced therapy for this disease," said Lisa von Moltke, M.D., Head of Research and Development and Chief Medical Officer at Zenas. "INDIGO adds to a substantial body of evidence demonstrating the broad potential of targeting CD19 and FcγRIIb in rheumatic and autoimmune diseases. We look forward to providing further updates on the development of obixelimab, including, topline results from our Phase 2 SunStone SLE trial later this year, and advancing ZB014, our half-life-extended CD19 and FcγRIIb antibody, toward clinical development."

About the Phase 3 INDIGO Trial

In INDIGO, 194 IgG4-RD patients with newly diagnosed or recurrent disease were randomized 1:1 to receive 250 mg of obixelimab or placebo subcutaneously weekly for 52 weeks. Patient demographics and clinical characteristics were generally balanced across arms at baseline.

INDIGO Met its Primary Endpoint of Reducing the Risk of IgG4-RD Flares

- Obixelimab demonstrated a highly statistically significant and clinically meaningful 56% reduction in the risk of IgG4-RD flare compared to placebo (HR 0.44; 95% CI 0.277–0.711; $p=0.0005$) during the 52-week randomized controlled period.
- A majority of patients treated with obixelimab (73.2%) remained flare-free through Week 52, compared to fewer than half (45.4%) of placebo-treated patients.
- These findings indicate a sustained reduction in flare risk over time following glucocorticoid withdrawal.

Obixelimab Demonstrated Highly Statistically Significant Activity on All Four Key Secondary Endpoints

- Time to first investigator-determined flare requiring rescue therapy was significantly longer with obixelimab and risk of investigator-determined disease flare requiring rescue therapy was reduced by 59% with obixelimab compared to placebo (HR 0.41; 95% CI 0.26-0.66; $p=0.0001$).
- The annualized adjudicated flare rate was 52% lower for obixelimab compared to placebo (HR 0.48; 95% CI 0.32-0.74; $p=0.0008$); 36 flares were observed in the obixelimab group compared with 72 in the placebo group.
- At Week 52, 37.1% of patients receiving obixelimab achieved complete remission compared

to 19.6% of patients who received placebo, representing a 17.7% improvement ($p=0.0049$). Complete remission was defined as no AC-determined flare, no treatment for flare and an IgG4-RD Responder Index (RI) of 0 or investigator determination of no active disease.

- At Week 52, mean cumulative glucocorticoid rescue therapy use was 329.5 mg across all obexelimab-treated patients and 929.8 mg for placebo-treated patients, representing an approximate 600 mg difference ($p=0.0042$; 65% reduction with obexelimab). Importantly, unlike IV administered B cell depleting agents used for the treatment of IgG4-RD, obexelimab was not administered with routine GC prophylaxis for hypersensitivity prior to dosing.

Obexelimab Lowered Glucocorticoid Toxicity

- Glucocorticoid toxicity was assessed using the Glucocorticoid Toxicity Index (GTI) and included 8 domains: body mass index, glucose tolerance, blood pressure, lipid metabolism, infection, GC myopathy, skin toxicity, and neuropsychiatric effects.
- At Week 52, the proportion of patients exceeding predefined glucocorticoid toxicity worsening thresholds was significantly lower in the obexelimab group compared to placebo, with 42.2% vs. 61.2% of patients reaching a ≥ 20 -point GTI-CWS increase ($p=0.0135$) and 28.9% vs. 49.4% reaching a ≥ 30 -point increase ($p=0.0090$).

Obexelimab Demonstrated Favorable Safety and Tolerability

- After an initial decrease that remained above the lower limit of normal (LLN), mean B-cell levels in obexelimab-treated patients stabilized and consistently remained above the LLN.
- Treatment-emergent adverse events (TEAEs) occurred in 97.9% of obexelimab-treated patients compared to 95.9% of placebo-treated patients.
- The incidence of Grade ≥ 3 TEAEs was lower with obexelimab (11.3%) compared to placebo (23.7%), and the incidence of serious adverse events was also lower for obexelimab (10.3%) compared with placebo (18.6%).
- Infections occurred in 53.6% of obexelimab-treated patients compared to 62.9% of placebo-treated patients.
- 3.5% of obexelimab doses resulted in injection-site reactions compared to 2.3% of placebo doses.
- Grade 2 or higher hypersensitivity occurred in 16.5% of obexelimab-treated patients compared to 11.3% of placebo-treated patients. All were Grade 2 except one Grade 3 reaction in an obexelimab-treated patient.
- There were no deaths in the obexelimab group and one death (1.0%) in the placebo group.

About Obexelimab

Obexelimab is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. This unique inhibitory mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of the B cell lineage in chronic autoimmune disease.

Obexelimab has been evaluated in eight clinical trials in a total of 383 subjects, including INDIGO. Obexelimab was well tolerated and demonstrated clinical activity across these clinical trials.

The registrational Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease met its primary endpoint and all four key secondary endpoints with high statistical significance. The trial continues to evaluate patients in the 3-year open label extension period which will further build upon the largest body of clinical data reported for IgG4-RD patients to date.

Enrollment in a randomized Phase 2 trial for Systemic Lupus Erythematosus is completed. Zenas expects to report topline results, including biomarker data from this trial in the fourth quarter of 2026.

About Zenas BioPharma

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Zenas' core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas' lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may broadly and effectively

address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib's mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas' earlier stage programs include ZB021, a novel, potentially best-in-class, oral small molecule IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit <https://zenasbio.com/> and follow us on [LinkedIn](#).

Zenas BioPharma Forward-Looking Statements

This press release contains "forward-looking statements" which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward looking statements include, but are not limited to, statements regarding the Company's product candidates, including the timing, progress and results of preclinical studies and clinical trials; the Company's ability to obtain and maintain regulatory approvals for obexelimab; the Company's belief that obexelimab may have an important role as a first time therapy in the long-term management of IgG4-RD; and the Company's plans for development of its pipeline and potential commercialization of obexelimab. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company's actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company's limited operating history, incurrence of substantial losses since the Company's inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company's need for substantial additional financing to achieve the Company's goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company's current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company's product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in the Company's current indications; the Company's ability to realize the benefits of the Company's current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company's ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction; the risk that the data from our clinical trials is not sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a biologics license application or other comparable submission or to obtain regulatory approval for our product candidates for which we seek approval in the U.S. or elsewhere, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company's dependence on the services of the Company's senior management and other clinical and scientific personnel, and the Company's ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company's ability to grow the Company's organization, and manage the Company's growth and expansion of the Company's operations; risks related to the manufacturing of the Company's product candidates, which is complex, and the risk that the Company's third-party manufacturers may encounter difficulties in production; the Company's ability to obtain and maintain sufficient intellectual property protection for the Company's product candidates or any future product candidates the Company may develop; the Company's reliance on third parties to conduct the Company's preclinical studies and clinical trials; the Company's compliance with the Company's obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company's product candidates; significant political, trade, and regulatory developments, including changes in relations between the U.S. and China; risks related to the operations of the Company's suppliers, many of which are located outside of the United States, including the Company's current sole contract manufacturing organization for obexelimab drug substance and drug product, WuXi Biologics (Hong Kong) Limited, and our partner, InnoCare, both of which are located in China; the risk that the Company's indebtedness resulting from the Company's loan agreement with Pharmakon Advisors LP, and the guarantors party to such agreement, or future indebtedness could adversely affect the Company's financial condition or restrict the Company's future operations; and other risks and uncertainties described in the section "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain, speak only as of the date of this press release and may prove incorrect. These statements are based upon information available to the Company as of the date of this press release and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company's control, these forward-looking statements should not be relied upon as guarantees of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

The Zenas BioPharma word mark, logo mark, and the "lightning bolt" design are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor and Media Contact:

Argot Partners

Zenas@argotpartners.com